Valuation Metrics Reflect Price Attractiveness Shift
Deep Health AI’s current price-to-earnings (P/E) ratio stands at a modest 5.79, significantly lower than many of its peers in the sector. This contrasts with previous valuations where the stock was considered expensive relative to earnings. The price-to-book value (P/BV) ratio has also contracted to 0.53, suggesting the stock is trading at roughly half its book value, a level that often signals undervaluation or market scepticism about asset quality.
Enterprise value to EBITDA (EV/EBITDA) and EV to EBIT ratios both hover around 13.84, which is moderate but higher than some very attractive peers such as Manoj Vaibhav (5.87) and T B Z (7.06). The PEG ratio, a measure of valuation relative to earnings growth, is exceptionally low at 0.08, indicating the market is pricing in minimal growth prospects for Deep Health AI.
Comparative Peer Analysis
When compared with sector peers, Deep Health AI’s valuation appears fair but less compelling. For instance, Shanti Gold and Motisons Jewel are rated as attractive with P/E ratios of 11.13 and 28 respectively, and EV/EBITDA multiples of 8.49 and 20.95. Other companies such as T B Z and Radhika Jeweltec are classified as very attractive, trading at P/E multiples below 11 and EV/EBITDA below 8. This peer comparison highlights that while Deep Health AI’s valuation has become more reasonable, it still lags behind several competitors in terms of price attractiveness.
Financial Performance and Returns
Deep Health AI’s return on capital employed (ROCE) is 7.83%, and return on equity (ROE) is 13.41%, figures that are modest and suggest limited efficiency in generating returns from capital and equity. The company also offers a dividend yield of 5.32%, which may appeal to income-focused investors despite the stock’s weak price momentum.
However, the stock’s price performance has been disappointing. Over the past year, Deep Health AI has declined by 52.17%, vastly underperforming the Sensex’s 4.84% fall. Year-to-date losses are even more severe at 68.2%, compared to a 9.21% gain in the benchmark index. This stark underperformance reflects both sector headwinds and company-specific challenges.
Market Capitalisation and Trading Range
As a micro-cap stock, Deep Health AI’s market capitalisation is relatively small, which often entails higher volatility and liquidity risks. The stock currently trades at ₹1.87, down from a previous close of ₹1.94, with a 52-week high of ₹10.29 and a low of ₹1.65. The recent day’s trading range was narrow, between ₹1.87 and ₹1.92, indicating subdued investor interest and limited price discovery.
Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!
- - Reliable Performer certified
- - Consistent execution proven
- - Large Cap safety pick
Rating Downgrade and Mojo Score Implications
MarketsMOJO recently downgraded Deep Health AI from a Sell to a Strong Sell rating on 12 Dec 2025, reflecting deteriorating fundamentals and weak price momentum. The company’s Mojo Score is a low 20.0, underscoring significant concerns about its near-term prospects. This downgrade signals caution for investors, especially given the stock’s micro-cap status and sector volatility.
Valuation Grade Evolution
Previously classified as expensive, Deep Health AI’s valuation grade has shifted to fair, indicating a more balanced price level relative to earnings and book value. This change may attract value-oriented investors seeking stocks trading below historical multiples. However, the low PEG ratio and weak returns caution that the market expects limited growth and profitability improvements.
Sector Context and Peer Performance
The Gems, Jewellery and Watches sector has seen mixed fortunes, with some companies maintaining attractive valuations and solid fundamentals. For example, Renaiss. Global and Manoj Vaibhav are rated very attractive with P/E ratios of 13.04 and 6.14 respectively, and EV/EBITDA multiples well below 10. These peers offer comparatively better growth prospects and operational efficiency, as reflected in their valuation premiums.
Investor Takeaway
While Deep Health AI’s valuation has become more reasonable, the stock’s weak price performance and fundamental challenges warrant caution. The downgrade to Strong Sell and low Mojo Score suggest that investors should carefully weigh risks before considering exposure. Comparatively, several peers in the sector offer more compelling valuations and stronger financial metrics, making them potentially superior alternatives for portfolio inclusion.
Holding Deep Health AI India Ltd from Gems, Jewellery And Watches? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Conclusion: Valuation Fair but Fundamentals Lag
Deep Health AI India Ltd’s transition from an expensive to a fair valuation grade marks a significant shift in market sentiment. Despite this, the company’s weak returns, low growth expectations, and recent rating downgrade temper enthusiasm. Investors should consider the stock’s relative underperformance against the Sensex and its peers before making investment decisions. While the valuation metrics may appear attractive on the surface, the underlying fundamentals and sector dynamics suggest a cautious approach is warranted.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
